RxDoctor Payments Data

Sarah Todd, MD

Dermatology · West Chester, PANPI 1003279142

Payments from drug & device makers

$10,426in general payments, 2019–2025

Across 643 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$2K
  • Sun Pharmaceutical Industries Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$764
  • LEO Pharma Inc.$527
  • UCB, Inc.$510
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$9,90495%
  • Education$5225%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,426 in reported general payments places this provider in the 80th percentile of 626 dermatology providers in Pennsylvania.

See all dermatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$519,295
Medicare patients
1,345
Services billed
8,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa26$533,164
TremfyaGuselkumab12$161,584
Dupixent PenDupilumab27$98,607
Clobetasol Propionate232$8,863
Tacrolimus63$7,020
Ketoconazole343$4,709
Tretinoin59$4,561
Ammonium Lactate256$4,238
Triamcinolone Acetonide315$3,914
Fluorouracil49$3,785
Doxycycline Hyclate108$2,130
Azelaic Acid22$2,076
Hydrocortisone131$1,773
Metronidazole53$1,666
Ciclopirox22$978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,910$161,58412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 626 dermatology providers in Pennsylvania.

Other dermatology in West Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →